Khi được bạn cho phép, chúng tôi sử dụng phân tích giới hạn, chú trọng quyền riêng tư để hiểu hành trình nghiên cứu nào hiệu quả. Chúng tôi không dùng trình theo dõi quảng cáo hoặc ghi lại phiên. Bạn có thể thay đổi lựa chọn này trong Tùy chọn. Đọc Chính sách quyền riêng tư.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
DHR — frequently asked questions
Is Danaher Corporation overvalued?
In our latest published analysis dated 2026-09-25, DHR looks meaningfully overvalued. The price recorded at analysis is 224 USD versus our fair value of 187 USD; the high endpoint is presented separately as potential value of 206 USD. That implies roughly 16.7% downside to fair value at that date.
Our latest published report, analyzed 2026-09-25, gives DHR a fair value of 187 USD and a potential value of 206 USD. The conclusion is triangulated across multiple valuation models and weighted by reliability for Danaher Corporation's archetype; it is a dated research output, not a live price.
Should I buy DHR now?
Our latest published rating for DHR, analyzed 2026-09-25, is Reduce. Danaher Corporation looks meaningfully overvalued at the analysis-date price of 224 USD versus fair value of 187 USD; potential value is 206 USD. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for DHR?
The dedicated bear-case section in our report analyzed 2026-09-25 documents Danaher Corporation's material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is DHR's rating?
Our latest published rating for DHR, analyzed 2026-09-25, is Reduce, with a published moat assessment of 9/10 (Wide). It reflects our fair value of 187 USD, the potential value of 206 USD, and the price recorded at analysis (224 USD).
Báo cáo này chưa được dịch. Hãy làm mới sau vài phút khi hàng đợi dịch xử lý xong.
§1 Tóm tắt điều hànhEN
Câu trả lời trong 30 giâyReduce
Giá so với giá trị
Giá
$223.90
Giá trị hợp lý
$186.58
Giá trị tiềm năng
$206.33
Tính đến
2026-09-25
Vì sao luận điểm có thể đúng
The most significant upside catalyst is an accelerated clearing of customer facility commissioning bottlenecks, allowing deferred chromatography resin shipments (> $100M) to deliver early in FY2027 alongside mid-teens bioprocessing order conversion and commercial batch manufacturing ramps,.
Danaher Corporation (NYSE: DHR) receives a Reduce rating. While Danaher maintains wide economic moats rooted in regulatory switching costs across Cytiva bioprocessing consumables and entrenched clinical diagnostics platforms, the market is pricing in an aggressive margin recovery that leaves no margin of safety against ongoing customer facility commissioning deferrals and endemic respiratory testing normalization.3
Against the market price of $223.90 as of 2026-09-25, the stock trades at an implied upside of -16.67% (a 20.00% valuation premium). At 23.81x NTM forward earnings, the current valuation assumes immediate operational reacceleration and rapid margin expansion toward 28.5%, discounting the execution friction associated with customer facility readiness and product normalization.3
Operational Trends and Segment Drivers: In Biotechnology ($7,293M FY2025 , $1,864M ),, underlying consumables and equipment orders are expanding at mid-teens rates. However, customer plant readiness challenges and production schedule revisions delayed multiple large chromatography resin shipments ($10M-$30M each, totaling >$100M) out of Q2/Q3 and into FY2027,. Concurrently, the Diagnostics segment ($9,941M FY2025 revenue, $2,650M operating income), contends with a 250 bps top-line drag in Q3 2026 from Cepheid respiratory testing normalization against a guided full-year baseline of about $1.6B.
Cash Generation and Capital Allocation: Danaher continues to demonstrate robust fundamental quality governed by the Danaher Business System (DBS). In FY2025, the company generated $6,416M in operating cash flow and $5,260M in free cash flow, alongside a strong balance sheet holding $4,615M in cash. Capital intensity remains disciplined, with capital expenditures of $1,156M (4.71% of revenue),. This cash engine enabled the strategic, early-closing acquisition of StatLab and ongoing share repurchases, supporting our modeled diluted share reduction of -1.83% CAGR,.4,5,6
Valuation Synthesis: Our synthesized fair value of $186.58 is anchored primarily on discounted earnings ($203.44 midpoint, 35% weight) and multi-stage moat fade ($204.45 midpoint, 25% weight), balanced by owner earnings ($162.55 midpoint, 25% weight) and forward earnings ($157.49 midpoint, 15% weight) discounted at an 8.54% cost of equity. While long-term EPS compounding of 9.2% remains achievable, the current share price provides no margin of safety against potential execution delays in commercial biomanufacturing restarts or prolonged procurement headwinds in High Growth Markets ($7,022M in FY2025),.2,4,7
Regulatory Lock-In and High Switching Costs in Bioprocessing
Cytiva purification chromatography resins and filtration media are specified directly within FDA and EMA approved biologic drug master files (DMFs), creating multi-decade switching barriers and mid-teens order growth across consumables and equipment,.4
Diagnostics generated $9,941M in FY2025 revenue and $2,650M in operating income,, supported by high single-digit momentum across Leica Biosystems, Radiometer, and non-respiratory Cepheid test menus.4,7
Danaher converted $6,416M in operating cash flow into $5,260M in free cash flow in FY2025,, funding accretive capital redeployment such as the early closing of StatLab and ongoing share repurchases.4,5,6
Khuyến nghị của hãng
Reduce. While Cytiva bioprocessing and Cepheid diagnostics possess wide economic moats, customer facility readiness deferrals pushing >$100M of resin shipments into FY2027, and respiratory testing normalization to $1.6B create an unfavorable risk-reward profile. Investors should reduce exposure and await a better margin of safety.3,4
Tổng quan công ty
The manufacture of many of its products is a highly exacting and complex process, and if the company directlies or indirectly encounter problems manufacturing products, its business and financial statements could suffer. The manufacture of many of its products is a highly exacting and complex process, due in part to strict regulatory requirements.
§2 Kịch bản tiêu cựcEN
A combined stress event evaluating a simultaneous 600 bps reduction in normalized operating margins, a 500 bps reduction in 5-year revenue growth, and a 20% multiple contraction demonstrates that Danaher's present valuation carries asymmetric downside. At $223.90, the stock trades 20.0% above the committee fair value midpoint of $186.58. While high free cash flow conversion ($5,260M in FY2025) and $4,615M in balance sheet cash mitigate insolvency risks, prolonged bioprocessing deferrals and respiratory drag leave no margin of safety for equity investors at prevailing trading levels.
High Growth Markets revenue contracts due to persistent VBP and hospital scrutiny7
Extended customer production schedule delays and site readiness challenges in biomanufacturing suppress Cytiva consumable volumes, while endemic respiratory testing falls below guided baselines and Chinese hospital procurement remains depressed,. Operating margins remain constrained near the FY2025 baseline of 19.09%, curtailing free cash flow growth.
Các cách luận điểm này có thể đổ vỡ
Protracted bioprocessing resin deferrals and respiratory testing deflation hold operating margins at reported FY2025 baseline, preventing modeled normalization to 28.5%.
Under this kill scenario, biopharmaceutical customer site readiness bottlenecks persist past FY2027 and endemic respiratory testing revenue falls below the guided $1.6B baseline,. Consolidated operating margin stays suppressed near the FY2025 level of 19.09%, breaching the 22.5% trigger threshold and imposing an estimated 24.5% fair value impairment.4,
Tín hiệu cảnh báo sớm cần theo dõi
Năm diễn biến có thể làm suy yếu luận điểm đầu tư của chúng tôi.
Danaher's wide economic moat is underpinned by two primary structural sources: customer switching costs in bioprocessing consumables (Cytiva) and an entrenched razor-and-blade installed base in clinical diagnostics (Beckman Coulter, Cepheid, Leica Biosystems, Radiometer). In Biotechnology ($7,293M revenue in FY2025), chromatography resins and filtration media are specified directly into commercial biologic Drug Master Files (DMFs) approved by the FDA and EMA. Because substituting these consumables requires costly, multi-year clinical revalidation and regulatory re-filing, drug developers face immense switching barriers over the multi-decade commercial manufacturing lifecycle of approved therapies.
Diagnostics ($9,941M revenue, $2,650M operating income in FY2025,) operates under a razor-and-blade commercial architecture. Proprietary instrument placements—such as the DxI 9000 clinical analyzer at Beckman Coulter and GeneXpert systems at Cepheid —drive recurring reagent and consumable purchases across hospital networks and clinical reference laboratories. The high capital cost and workflow integration of automated instruments create substantial procedural switching barriers, securing predictable high-margin consumable streams that buffer macro cyclicality.
The Danaher Business System (DBS) continuous improvement culture reinforces structural advantages through operational efficiency and disciplined integration of strategic bolt-ons, exemplified by the early closing and commercial rollout of StatLab. Operating cash flow generation of $6,416M and free cash flow of $5,260M in FY2025, provide the balance-sheet firepower to fund continuous R&D and targeted acquisitions, compounding the firm's competitive moat against peers like Thermo Fisher and Agilent.
Lợi nhuận kinh tế
Danaher's economic profit generation remains firmly positive, supported by FY2025 operating income of $4,690M and free cash flow of $5,260M on a capital expenditure base of $1,156M,,. With a computed WACC of 7.97% and cost of equity of 8.54%, the business comfortably earns returns in excess of its cost of capital. However, at the current enterprise valuation ($223.90 share price, $157.31B market cap,), the market price fully capitalizes these economic profits, creating a 20.0% valuation premium over the synthesized fair value of $186.58.2,3
9/ 10
Wide
Sources of advantage
01Bioprocessing Consumable Regulatory DMF Lock-In — Cytiva chromatography resins and filtration media are embedded into FDA/EMA biologic drug master files, creating prohibitive clinical re-validation costs,.Wide
02Clinical Diagnostics Installed Base and Proprietary Consumables — Entrenched diagnostic instruments generated $9,941M of revenue and $2,650M of operating income in FY2025 through multi-year proprietary reagent contracts,.Wide
The highlighted cell is Fair value when every assumption sits at its base level ($186.58). Each row and column shows what Fair value becomes when one assumption moves.
Consolidated core revenue expands at 3%-4% in FY2026 and reaccelerates to 8.0% in FY2027 as customer batch manufacturing schedules normalize and deferred chromatography resin shipments deliver,. Operating margins progress from 19.09% in FY2025 to 26.5% in FY2026 and reach 28.5% over the forecast horizon,. Free cash flow conversion remains above 100%, funding debt service and regular share repurchases.4,5,6
A substantial beat driven by early bioprocessing resin shipment recognition and non-respiratory diagnostic expansion would validate faster operating margin recovery toward historical peak levels.
Đúng kỳ vọng
Maintain Reduce; Maintain trimmed portfolio weightings, verify bioprocessing backlog conversion milestones, and avoid deploying incremental capital above fair value.
Results meeting management guidance confirm gradual multi-year normalization but leave valuation stretched at a premium to Fair value.
Hụt
Downgrade the rating; Execute further reductions in portfolio exposure, audit bioprocessing order intake trends, and test liquidity buffers against downside scenarios.
A guidance cut or revenue miss signaling renewed bioprocessing cancellations or accelerated respiratory test erosion would trigger further valuation multiple compression toward historical troughs.
Chất lượng lợi nhuận
Earnings quality is high, evidenced by an FCF-to-net income conversion ratio exceeding 145% ($5,260M FCF on $3,614M net income in FY2025,). Operating earnings are backed by tangible cash collections across recurring diagnostic reagent and bioprocessing consumable contracts, with minimal reliance on non-cash adjustments.5,6
Danaher demonstrates exceptional cash flow conversion, generating $6,416M in cash flow from operations and $5,260M in free cash flow in FY2025,. Capital expenditures of $1,156M represented just 4.71% of total revenue ($24,568M),, underscoring the asset-light nature of its consumable-heavy operating model. FCF conversion of net income ($3,614M in FY2025) exceeded 145%, supported by disciplined working capital management and stable non-cash depreciation of $2,447M.5,6
Returns on invested capital are trending upward from FY2025 trough levels as operating margins normalize from 19.09% toward the guided 26.5% Q3 baseline and long-term 28.5% target, driven by high-margin consumable mix recovery in Biotechnology ($1,864M operating profit in FY2025).
ROIC comfortably exceeds Danaher's computed WACC of 7.97% and cost of equity of 8.54%, confirming positive economic value creation across normalized operating cycles.
Biotechnology Margins Face Operational Leverage Recovery
Biotechnology delivered $1,864M of operating income on $7,293M of revenue (25.56% margin) in FY2025,, depressed from historic 30%+ levels.
Fulfillment of deferred resin shipments and mid-teens order growth will yield substantial operational margin expansion.
Doanh thu mới nhất24,6 T US$CAGR doanh thu +4,3%
Biên hoạt động19,1%10 kỳ tài chính
Dòng tiền tự do mới nhất5,3 T US$FY2025
Nợ ròng13,8 T US$FY2025
Phân tích báo cáo kết quả kinh doanhQuy mô kinh doanh chuyển thành lợi nhuận báo cáo như thế nào.30 thg 6, 2026
StockMarketAgent.AI
Doanh thu6,3 T US$Giá vốn doanh thu−2,7 T US$Lợi nhuận gộp3,6 T US$Chi phí hoạt động−2,5 T US$Lợi nhuận hoạt động1,1 T US$Các khoản ngoài hoạt động và thuế−257 Tr US$Lợi nhuận ròng870 Tr US$
Dữ liệu lịch sử tài chính
Doanh thu
6.265.000.000 US$
Giá vốn doanh thu
2.654.000.000 US$
Lợi nhuận gộp
3.611.000.000 US$
Chi phí hoạt động
2.484.000.000 US$
Lợi nhuận hoạt động
1.127.000.000 US$
Các khoản ngoài hoạt động và thuế
-257.000.000 US$
Lợi nhuận ròng
870.000.000 US$
Tổng quan bảng cân đối kế toánCách tài sản đã báo cáo được nắm giữ và tài trợ trong kỳ đã chọn.
StockMarketAgent.AI
Cơ cấu tài sảnNguồn tài trợ
Tổng tài sản83,5 T US$Tiền mặt4,6 T US$Tài sản ngắn hạn12,8 T US$Tổng nợ phải trả30,9 T US$Nợ ngắn hạn6,8 T US$Vốn chủ sở hữu52,5 T US$
Dữ liệu phân tích bảng cân đối kế toán
Tổng tài sản
83.464.000.000 US$
Tiền mặt
4.615.000.000 US$
Tài sản ngắn hạn
12.756.000.000 US$
Tổng nợ phải trả
30.930.000.000 US$
Nợ ngắn hạn
6.807.000.000 US$
Vốn chủ sở hữu
52.541.000.000 US$
Cầu nối dòng tiềnDòng tiền từ hoạt động chuyển thành dòng tiền tự do như thế nào trong FY2025.
StockMarketAgent.AI
Đối chiếu dòng tiền hoạt động
Lợi nhuận ròng3,6 T US$Khấu hao và phân bổ+2,4 T US$Thù lao bằng cổ phiếu+298 Tr US$Điều chỉnh hoạt động khác+57 Tr US$Dòng tiền hoạt động6,4 T US$
Đối chiếu tiền đầu kỳ đến cuối kỳ
Tiền đầu kỳ2,1 T US$Dòng tiền hoạt động+6,4 T US$Dòng tiền đầu tư−1,2 T US$Dòng tiền tài chính−3 T US$Ảnh hưởng tỷ giá+278 Tr US$Tiền cuối kỳ4,6 T US$
6,4 T US$ − 1,2 T US$Dòng tiền tự do 5,3 T US$
Dữ liệu cầu nối dòng tiền
Lợi nhuận ròng
3.614.000.000 US$
Dòng tiền vào từ hoạt động
6.416.000.000 US$
Khấu hao và phân bổ
2.447.000.000 US$
Thù lao bằng cổ phiếu
298.000.000 US$
Điều chỉnh hoạt động khác
57.000.000 US$
Dòng tiền hoạt động
6.416.000.000 US$
Tiền sẵn có
8.772.000.000 US$
Tiền đầu kỳ
2.078.000.000 US$
Ảnh hưởng tỷ giá
278.000.000 US$
Dòng tiền ra từ đầu tư
1.196.000.000 US$
Capex
1.156.000.000 US$
Hoạt động đầu tư khác
40.000.000 US$
Dòng tiền ra từ tài chính
2.961.000.000 US$
Phát hành nợ ròng
1.045.000.000 US$
Mua lại cổ phiếu
3.088.000.000 US$
Cổ tức đã trả
878.000.000 US$
Hoạt động tài chính khác
40.000.000 US$
Tiền cuối kỳ
4.615.000.000 US$
Dòng tiền đầu tư
-1.196.000.000 US$
Dòng tiền tài chính
-2.961.000.000 US$
Doanh thu theo phân khúc hoạt độngTỷ trọng trong tổng doanh thu của 2025-12-31.
24,6 T US$Tổng doanh thu
Doanh thu theo phân khúc hoạt độngTỷ trọng
Diagnostics9,9 T US$40,5%+1,6% so với cùng kỳ
Life Sciences7,3 T US$29,9%+0,1% so với cùng kỳ
Biotechnology7,3 T US$29,7%+7,9% so với cùng kỳ
Nguồn: SEC EDGAR · Nộp ngày 2026-02-24 · SEC EDGAR
Dữ liệu cơ cấu doanh thu: Doanh thu theo phân khúc hoạt động
Doanh thu theo phân khúc hoạt động
Doanh thu
Tỷ trọng
so với cùng kỳ
Diagnostics
9,9 T US$
40,5%
1,6%
Life Sciences
7,3 T US$
29,9%
0,1%
Biotechnology
7,3 T US$
29,7%
7,9%
Doanh thu theo khu vựcTỷ trọng trong tổng doanh thu của 2025-12-31.
24,6 T US$Tổng doanh thu
Doanh thu theo khu vựcTỷ trọng
North America10,4 T US$42,2%+0,6% so với cùng kỳ
High Growth Markets7 T US$28,6%+2,2% so với cùng kỳ
Western Europe5,9 T US$24,2%+8,8% so với cùng kỳ
Other Developed Markets1,3 T US$5,1%−0,1% so với cùng kỳ
Nguồn: SEC EDGAR · Nộp ngày 2026-02-24 · SEC EDGAR
Dữ liệu cơ cấu doanh thu: Doanh thu theo khu vực
Doanh thu theo khu vực
Doanh thu
Tỷ trọng
so với cùng kỳ
North America
10,4 T US$
42,2%
0,6%
High Growth Markets
7 T US$
28,6%
2,2%
Western Europe
5,9 T US$
24,2%
8,8%
Other Developed Markets
1,3 T US$
5,1%
-0,1%
Doanh thu và lợi nhuậnQuy mô kinh doanh chuyển thành lợi nhuận báo cáo như thế nào.
Tiền mặt và nợThanh khoản sẵn có so với tổng dư nợ.
Tạo dòng tiềnDòng tiền hoạt động so với dòng tiền tự do.
Khả năng sinh lờiDiễn biến biên gộp, biên hoạt động và biên ròng.
Dữ liệu tài chính tại thời điểm được dùng trong phân tích ngày 2026-09-25.
Dữ liệu lịch sử tài chính
Kỳ
Doanh thu
EBITDA
Lợi nhuận ròng
Dòng tiền hoạt động
Dòng tiền tự do
Capex
Khấu hao và phân bổ
Thù lao bằng cổ phiếu
Mua lại cổ phiếu
Cổ tức đã trả
Phát hành nợ ròng
Dòng tiền đầu tư
Dòng tiền tài chính
Tiền đầu kỳ
Tiền cuối kỳ
Tiền mặt và đầu tư
Tổng nợ
Biên hoạt động
ROIC
WACC
Chênh lệch ROIC−WACC
2016-12-31
16,9 T US$
3,9 T US$
2,6 T US$
3,5 T US$
2,9 T US$
589,6 Tr US$
1,1 T US$
129,8 Tr US$
—
399,8 Tr US$
—
-5,2 T US$
2 T US$
—
963,7 Tr US$
963,7 Tr US$
12,3 T US$
16,2%
—
6,0%
—
2017-12-31
15,5 T US$
4,3 T US$
2,5 T US$
3,5 T US$
2,9 T US$
570,7 Tr US$
1,1 T US$
127,1 Tr US$
—
378,3 Tr US$
—
-843,4 Tr US$
-3,1 T US$
963,7 Tr US$
630 Tr US$
630,3 Tr US$
10,5 T US$
16,6%
—
5,9%
—
2018-12-31
17 T US$
4,3 T US$
2,7 T US$
4 T US$
3,4 T US$
584 Tr US$
1,2 T US$
138 Tr US$
—
433 Tr US$
—
-2,9 T US$
-797 Tr US$
630 Tr US$
788 Tr US$
787,8 Tr US$
9,7 T US$
17,9%
—
6,4%
—
2019-12-31
17,9 T US$
4,6 T US$
3 T US$
4 T US$
3,3 T US$
636 Tr US$
1,2 T US$
159 Tr US$
—
527 Tr US$
—
-1,2 T US$
16,4 T US$
788 Tr US$
19,9 T US$
19,9 T US$
21,7 T US$
18,3%
—
5,3%
—
2020-12-31
22,3 T US$
6,5 T US$
3,6 T US$
6,2 T US$
5,4 T US$
791 Tr US$
1,8 T US$
187 Tr US$
—
615 Tr US$
—
-21,2 T US$
1 T US$
19,9 T US$
6 T US$
6 T US$
21,2 T US$
19,0%
—
3,9%
—
2021-12-31
24,8 T US$
10 T US$
6,4 T US$
8,4 T US$
7,1 T US$
1,2 T US$
2,1 T US$
184 Tr US$
—
742 Tr US$
—
-13 T US$
1,3 T US$
6 T US$
2,6 T US$
2,6 T US$
22,2 T US$
25,7%
—
4,6%
—
2022-12-31
26,6 T US$
9,5 T US$
7,2 T US$
8,5 T US$
7,4 T US$
1,1 T US$
2,1 T US$
295 Tr US$
0 US$
818 Tr US$
-1,7 T US$
-2,2 T US$
-2,6 T US$
2,6 T US$
6 T US$
6 T US$
19,7 T US$
28,3%
—
7,2%
—
2023-12-31
23,9 T US$
5,2 T US$
4,8 T US$
7,2 T US$
5,8 T US$
1,4 T US$
2,2 T US$
306 Tr US$
0 US$
821 Tr US$
-1,6 T US$
-7,1 T US$
-273 Tr US$
6 T US$
5,9 T US$
5,9 T US$
18,4 T US$
21,8%
—
7,1%
—
2024-12-31
23,9 T US$
7,3 T US$
3,9 T US$
6,7 T US$
5,3 T US$
1,4 T US$
2,4 T US$
288 Tr US$
6 T US$
768 Tr US$
-1,7 T US$
-2 T US$
-8,4 T US$
5,9 T US$
2,1 T US$
2,1 T US$
16 T US$
20,4%
—
7,7%
—
2025-12-31
24,6 T US$
6,9 T US$
3,6 T US$
6,4 T US$
5,3 T US$
1,2 T US$
2,4 T US$
298 Tr US$
3,1 T US$
878 Tr US$
1 T US$
-1,2 T US$
-3 T US$
2,1 T US$
4,6 T US$
4,6 T US$
18,4 T US$
19,1%
—
7,6%
—
§9 So sánh định giá với các doanh nghiệp cùng ngành
Giá trị hợp lýReport-date price
Danaher CorporationDHR
Giá / giá trị hợp lý
Giá trị hợp lý186,58 US$Report-date price223,9 US$
Ngày đánh giá
Hào kinh tếWide
Bảng điểm đầu tư64 / 100
Thermo Fisher Scientific Inc.TMO
Giá / giá trị hợp lý
Giá trị hợp lý318,21 US$Report-date price656,45 US$
Ngày đánh giá
Hào kinh tếWide
Bảng điểm đầu tư61 / 100
Illumina, Inc.ILMN
Giá / giá trị hợp lý
Giá trị hợp lý119,53 US$Report-date price259,19 US$
Ngày đánh giá
Hào kinh tếWide
Bảng điểm đầu tư64 / 100
Danaher CorporationDHR
Giá / giá trị hợp lý
Giá trị hợp lý186,58 US$Report-date price223,9 US$
Danaher Corporation (DHR) trades at 23.8x forward earnings against a peer median of 28.1x. Its EV/EBITDA of 22.5x compares with a peer median of 25.1x. The comparison uses 4 peers: Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc. and IDEXX Laboratories Inc., as of 2026-09-25.
§10 Ngành và chu kỳEN
Pha chu kỳ
Trough
Industry benchmarks indicate a capex-to-revenue ratio of 4.5% and capex-to-depreciation of 0.80, demonstrating that the life sciences and bioprocessing equipment sector is operating at replacement levels following pandemic-era capacity overbuild. Danaher's FY2025 capex of $1,156M against revenue of $24,568M yields a 4.71% capex-to-revenue ratio,, aligning with this restrained reinvestment regime.6
Chu kỳ tăng giá
In an accelerating upcycle, biopharmaceutical capacity expansions resume aggressively, customer greenfield facilities come online ahead of schedule, chromatography resin pushouts (> $100M) convert fully into FY2027 deliveries, and Chinese hospital procurement re-accelerates, driving organic revenue growth above 8%,.
Chu kỳ giảm giá
In a protracted downcycle, pharmaceutical capital rationing persists, clinical trial delays defer commercial batch scale-up, and hospital equipment budgets freeze, capping consolidated core growth below 3% and keeping operating margins trapped in the low-20% range,.
Xu hướng dài hạn
Xu hướng
Tác động
Ghi chú
Biologics and Monoclonal Antibody Expansion
positive
Expanding global pipeline of biologic therapeutics and biosimilars drives multi-decade consumable demand for Cytiva purification resins and filtration media.
Centralized Hospital Procurement and Healthcare Cost Containment
Định vị
Danaher is uniquely positioned as a high-margin consumables supplier (~80% recurring revenue base), mitigating capital equipment cyclicality through recurring reagent and chromatography media demand.4
§11 Quản lý vị thếEN
Quy mô vị thế
0-1%
Under a Reduce rating with the market price ($223.90) trading at a 20.0% premium to the synthesized fair value of $186.58, capital allocation should be restricted to a minimal underweight posture. Investors should trim existing holdings toward a 0-1% portfolio allocation to limit downside risk while awaiting a more favorable entry valuation.3
Rủi ro
Risk management focuses on capital preservation and downside limitation. With total debt of $27.86B, upcoming debt service is well insulated by $4.62B in cash and $5.26B in annual free cash flow,. However, portfolio risk stems from valuation vulnerability: Danaher's forward P/E of 23.81x leaves minimal cushion against shipment deferrals or macro healthcare spending pauses. Maintaining strict position weight limits (0-1%) and disciplined trim thresholds safeguards capital.
Đợt vào lệnh
Mức
Hành động
Lý do
Initiate initial tracking position
$170.01 - $186.58
Accumulate selectively on fundamental confirmation
Corresponds to the midpoint of synthesized intrinsic value ($186.58), contingent on verified acceleration in bioprocessing order conversions.
Long-term compounders with an attractive historical cost basis may hold core positions given Danaher's wide economic moats in Cytiva bioprocessing and Cepheid diagnostics, supported by $5.26B in annual free cash flow. However, fresh capital deployment should be paused until market price ($223.90) approaches fair value ($186.58),.3,5
Valuation-Sensitive & Tactical Investor
Avoid
Valuation-sensitive investors should avoid initiating new positions or actively trim existing holdings. Danaher trades at 23.81x forward earnings, representing a 20.00% premium to our $186.58 fair value midpoint. With >$100M of bioprocessing resin shipments pushed into FY2027 and ongoing respiratory headwinds, the near-term risk-reward is asymmetric to the downside.3,4
Total Return & Income-Oriented Investor
Avoid
With a modest dividend payout ($1.60 per share) and capital allocation focused on M&A and share repurchases, total returns are driven primarily by capital appreciation. At current prices, capital appreciation potential is negative (-16.67% implied upside to fair value),, making total return prospects unattractive until valuation multiples normalize.3
§14 Khuyến nghị cuối cùngEN
Hành động
Giảm
We recommend reducing exposure to Danaher Corporation (DHR). While Danaher commands wide economic moats in bioprocessing and diagnostics, the market has priced in a frictionless recovery to 28.5% operating margins and 8.04% top-line growth in FY2027.1,3
Near-term operational friction remains unaddressed by current valuation multiples. Biopharmaceutical customer facility readiness challenges have shifted more than $100M of high-margin chromatography resin shipments into FY2027,, while endemic respiratory testing deflation creates a 250 bps headwind in Q3,. At 23.81x NTM forward earnings, the risk-reward profile is skewed unfavorably, justifying a trim of existing positions to reallocate capital into assets with a wider margin of safety.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Private notes
Visible only to you. Synced to this device.
0 chars
Sources
The records this analysis drew on, as they stood when it was run.
Analyst consensusData as of 2026-09-25 · Published 2026-09-25 · Provider-adjusted · cited for 1 figuresCited in Khuyến nghị cuối cùng
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Prolonged biopharmaceutical customer facility readiness delays and China hospital procurement headwinds freeze consolidated core revenue growth at low single digits.
Persistent commissioning delays in biomanufacturing plants combined with ongoing centralized volume-based procurement and healthcare anti-corruption inspections across Chinese hospitals, constrain 5-year consolidated core revenue growth below the 3.0% trigger threshold, driving an estimated 28.0% fair value impairment.4,7
FV impact
-1.1%
Revenue and EPS growth 5 points lower for five years
Trigger
Within 24 months
Valuation derating toward historical and peer lower bounds as earnings growth fails to reaccelerate above GDP.
If earnings reacceleration stalls and Danaher's growth converges toward broader GDP expansion, market multiples derate from the current forward P/E of 23.81x toward the historical lower bound of 18.0x, generating a 20.0% fair value impairment.3
FV impact
-2.5%
Terminal multiple 20% lower
Trigger
Within 18 months
Fails to show progression toward modeled 26.5% Q3 guidance benchmark and long-term 28.5% normalization target.
China High Growth Markets core growth rebounds to 8%-10%7
StatLab and new 510(k) assays exceed accretion expectations4
Rapid absorption of bioprocessing inventory leads to accelerated commercial batch manufacturing and new greenfield quoting. Specialty diagnostics maintain high single-digit momentum driven by DxI 9000 and Cepheid non-respiratory assays, while China hospital procurement rebounds. Operating margins expand ahead of schedule, driving strong double-digit earnings growth.4
Hiện tạiGuided to ~26.5% for Q3 2026.
Vì sao quan trọng
Tracking margin expansion from the 19.09% GAAP baseline in FY2025 toward the 26.5% Q3 target tests operational leverage.4,6
Hiện tạiGuided to ~$1.6B full year baseline with headwinds abating in Q4,.
Vì sao quan trọng
Determines when the 250 bps headwind in Q3 fully dissipates, allowing underlying core diagnostics growth to shine.4
04
Chỉ số:
High Growth Markets and China Hospital Demand
Hiện tạiManagement notes policy headwinds are beginning to lessen in late 2026.
Vì sao quan trọng
High Growth Markets represent 28.6% of revenue ($7,022M in FY2025); easing of VBP and anti-corruption campaigns would unlock diagnostic instrument sales.7
05
Chỉ số:
StatLab Acquisition Accretion and Menu Expansion
Hiện tạiClosed early; tracking to add $0.07-$0.08 to FY2026 adjusted EPS.
Vì sao quan trọng
Tests M&A deployment efficacy, new 510(k) assay launches, and high single-digit growth expectations,.4
Management balances strategic M&A, debt deleveraging, and share repurchases. The early closing of the StatLab acquisition in 2026 adds $0.07-$0.08 to EPS and bolsters specialty diagnostics. Concurrently, share repurchases reduced diluted share count from 743.1M in FY2023 to 716.1M in FY2025 (-1.84% CAGR),, with shares outstanding standing at 702.99M as of September 2026. Total debt of $27.86B is supported by $4.62B in balance sheet cash, and robust annual free cash flow.
Diagnostics Acts as the Primary Operating Profit Engine
Diagnostics generated $2,650M in operating income on $9,941M revenue (26.66% margin) in FY2025,.
Diagnostics provides consistent cash flow ballast while Life Sciences and Biotechnology work through cyclical transitions.
